Most Recent
A Federal Court judge on Thursday dismissed a "flimsy" application by IT firm EIFY to launch an appeal out of time in a software copyright dispute with 3D Safety Services.
Australian bicycle manufacturer Reid Cycles is appealing an IP Australia decision to reject its application for the Condor trade mark after a successful opposition by UK-based Condor Cycles.
Generic pharmaceutical company Aspen Pharma has resolved a patent infringement case brought by the maker of the anti-depressant Lexapro, according to a Federal Court order Tuesday.
A judge has granted F. Hoffman La-Roche's request for a temporary order blocking Sandoz from making or selling a biosimilar version of its patented biologic used to treat various cancers and rheumatoid arthritis.
Triclops Technologies has filed an appeal less than one month after the Federal Court dismissed its case alleging a rival infringed its patent for an industrial machine safety system that uses laser fields to detect hazards, but found the patent was valid.
The Australian Manuka Honey Association has introduced a new standard for verifying authentic, Australian manuka honey, as the group continues its battle with New Zealand over intellectual property rights to the expensive superfood.
Two GPS tracking patents at the heart of a David vs. Goliath battle between Domino's and a Sydney-based startup were foreshadowed by a patent owned by Uber, the pizza chain giant told a court Friday.
IP Australia has denied liquor producer Patron Spirits' opposition to rival Fernbrew's trade mark for Pirate Bay Rum, saying the mark was not likely to be confused with Patron's Pyrat brand of rum.
IP Australia has ruled in part that cheese branded with the Asiago label need not be manufactured in the Asiago region in Italy, striking down an opposition to a trade mark filed by cheese producer Sartori Company.
Three generic drug manufacturers cannot claim damages for an injunction barring the release of cheaper versions of Effexor-XR, even if the injunction was later overturned, pharmaceutical giant Wyeth told a judge on day two of a six-week trial over its blockbuster antidepressant.